English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Abilify Maintena (aripiprazole) – Conditions or restrictions regarding supply and use - N05AX12

Updated on site: 11-Jul-2017

Medication nameAbilify Maintena
ATC CodeN05AX12
Substancearipiprazole
ManufacturerOtsuka Pharmaceutical Europe Ltd

A.MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

H. Lundbeck A/S

Ottiliavej 9

DK 2500 Valby

Denmark

Elaiapharm

2881 Route des Crêtes Z.I Les Bouillides Sophia Antipolis

06550 Valbonne France

B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Periodic safety update reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 26581

    prescription drugs listed